PPCB (Propanc Biopharma) Cyclically Adjusted PB Ratio: (As of Jul. 03, 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.79
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Propanc Biopharma  (NAS:PPCB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Propanc Biopharma Cyclically Adjusted PB Ratio Related Terms


Propanc Biopharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Cyclically Adjusted PB Ratio Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PPCB vs GRI, BGMS, SPRC: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Propanc Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Propanc Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Cyclically Adjusted PB Ratio falls into.


PPCB
29GF Score
Propanc Biopharma Inc PPCB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Propanc Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Propanc Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=11.245/137.0353*137.0353
=11.245

Current CPI (Mar. 2026) = 137.0353.

Propanc Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 0.000
201609 0.000 0.000
201612 0.000 0.000
201703 0.000 0.000
201706 0.000 0.000
201709 0.000 0.000
201712 0.000 0.000
201803 0.000 0.000
201806 0.000 0.000
201809 0.000 0.000
201812 0.000 0.000
201903 0.000 0.000
201906 0.000 0.000
201909 0.000 0.000
201912 0.000 0.000
202003 0.000 0.000
202006 0.000 0.000
202009 0.000 0.000
202012 0.000 0.000
202103 0.000 0.000
202106 0.000 0.000
202109 0.000 0.000
202112 0.000 0.000
202203 0.000 0.000
202206 0.000 0.000
202209 0.000 0.000
202212 0.000 0.000
202303 0.000 0.000
202306 0.000 0.000
202309 0.000 0.000
202312 0.000 0.000
202403 0.000 0.000
202406 0.000 0.000
202409 -4,108.000 129.143 -4,359.058
202412 -4,159.000 130.173 -4,378.256
202503 38.991 131.042 40.774
202506 29.970 131.551 31.220
202509 28.049 133.771 28.733
202512 19.428 135.069 19.711
202603 11.245 137.035 11.245

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.79
Price